Stereotactic ablative radiation therapy prior to liver transplantation in hepatocellular carcinoma

被引:13
|
作者
Guarneri, Alessia [1 ]
Franco, Pierfrancesco [1 ]
Romagnoli, Renato [2 ]
Trino, Elisabetta [1 ,2 ]
Mirabella, Stefano
Molinaro, Luca [3 ]
Rizza, Giorgia [2 ]
Filippi, Andrea Riccardo [1 ]
Carucci, Patrizia [4 ]
Salizzoni, Mauro [2 ]
Ricardi, Umberto [1 ]
机构
[1] Univ Turin, Sch Med, Radiat Oncol, Dept Oncol, Via Genova 3, I-10126 Turin, Italy
[2] Univ Turin, Dept Surg Sci, Liver Transplantat Ctr, Turin, Italy
[3] Univ Turin, Dept Med Sci, Pathol Unit, Turin, Italy
[4] AOU Citta Salute & Sci, Dept Gastrohepatol, Turin, Italy
来源
RADIOLOGIA MEDICA | 2016年 / 121卷 / 11期
关键词
Hepatocellular carcinoma; Liver transplantation; Stereotactic ablative radiotherapy; Bridge; Local control; Surgery; CANCER; RADIOTHERAPY; BRIDGE; CIRRHOSIS;
D O I
10.1007/s11547-016-0670-1
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Stereotactic ablative radiotherapy (SABR) is a safe treatment approach for hepatocellular carcinoma (HCC) with comparable effectiveness to other local therapies. Only scant information is available concerning the role of SABR prior to liver transplantation (LT) for HCC. We present a consecutive case series investigating the role of SABR as a bridge or downstaging option in HCC patients subsequently submitted to LT. Between September 2012 and May 2014, 8 patients for a total of 13 lesions underwent SABR prior to LT. Inclusion criteria were a pathological or radiological diagnosis of HCC, lesion size aecurrency sign6 cm or lesion number aecurrency sign3 with a total diameter aecurrency sign6 cm, no extrahepatic metastases, Child-Pugh class A-B, ECOG performance status aecurrency sign1. Patients were prescribed 36-48 Gy in 3-5 fractions (8 Gy x 5 fractions or 16 Gy x 3 fractions), in 3-5 consecutive days according to clinical and dosimetric decision making. Radiological response was evaluated according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST). Pathological response was assessed through the rate of tumor necrosis relative to the total tumor volume. Acute and late toxicities were scored using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4 (CTCAE v 4.0). Among the 13 pathologically evaluated lesions, 8 (61.5 %) lesions had a complete response 2 (15.3 %) had a minimal pathological response and other 2 (15.3 %) showed stable disease. The remaining lesion had a significant pathological response. Maximum detected toxicity included a G2 GGT increase in two patients (at 1 and 3 months respectively). One patient developed a non-classic RILD with a fivefold increase in transaminase enzymes level and a shift in Child-Pugh category from B7 to C10 due to bilirubin increase. Only one modification in the surgical strategy was needed during LT. SABR proved to be a safe and effective local therapy prior to LT in HCC patients. Prospective controlled clinical trials are needed to evaluate its efficacy compared to other local therapies in this setting.
引用
收藏
页码:873 / 881
页数:9
相关论文
共 50 条
  • [1] Stereotactic ablative radiation therapy prior to liver transplantation in hepatocellular carcinoma
    Alessia Guarneri
    Pierfrancesco Franco
    Renato Romagnoli
    Elisabetta Trino
    Stefano Mirabella
    Luca Molinaro
    Giorgia Rizza
    Andrea Riccardo Filippi
    Patrizia Carucci
    Mauro Salizzoni
    Umberto Ricardi
    La radiologia medica, 2016, 121 : 873 - 881
  • [2] ROLE OF STEREOTACTIC BODY RADIATION THERAPY PRIOR TO LIVER TRANSPLANTATION IN HEPATOCELLULAR CARCINOMA
    White, Mattie
    Halima, Ahmed
    Aucejo, Federico N.
    Quintini, Christiano
    Stephans, Kevin
    Menon, K. V. Narayanan
    HEPATOLOGY, 2022, 76 : S533 - S533
  • [3] Stereotactic body radiation therapy as an ablative treatment for inoperable hepatocellular carcinoma
    Huertas, Andres
    Baumann, Anne-Sophie
    Saunier-Kubs, Fleur
    Salleron, Julia
    Oldrini, Guillaume
    Croise-Laurent, Valerie
    Barraud, Helene
    Ayav, Ahmed
    Bronowicki, Jean-Pierre
    Peiffert, Didier
    RADIOTHERAPY AND ONCOLOGY, 2015, 115 (02) : 211 - 216
  • [4] Stereotactic Body Radiation Therapy for Recurrent, Isolated Hepatocellular Carcinoma Lymph Node Metastasis With or Without Prior Liver Transplantation
    Walburn, Tyler
    Moon, Andrew M.
    Hayashi, Paul H.
    Gerber, David
    Sanoff, Hanna K.
    McGinty, Katrina A.
    Mauro, David
    Tepper, Joel
    Wang, Kyle
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (08)
  • [5] Stereotactic Ablative Body Radiation Therapy for Previously Untreated Solitary Hepatocellular Carcinoma in Patients With Liver Disease
    Takeda, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S320 - S321
  • [6] Liver Stereotactic Body Radiation Therapy (SBRT) to Downstage Patients with Hepatocellular Carcinoma prior to Liver Transplant
    Parker, S. M.
    Halima, A.
    Woody, N. M.
    Stephans, K. L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E332 - E332
  • [7] Stereotactic Body Radiation Therapy as a Bridging Therapy for Hepatocellular Carcinoma in Patients Listed for Liver Transplantation
    Pasquier, Ludwig
    Bernadou, Guillemette
    Dujardin, Fanny
    Scotto, Beatrice
    Bucur, Petru
    Perarnau, Jean Marc
    Soule, Mathilde
    de Muret, Anne
    Silvain, Christine
    Calais, Gilles
    Salame, Ephrem
    TRANSPLANTATION, 2015, 99 : 289 - 289
  • [8] Stereotactic Ablative Radiation Therapy Combined With Incomplete Transarterial Chemoembolization in Hepatocellular Carcinoma
    Paik, E.
    Kim, M.
    Jang, W.
    Seo, Y.
    Cho, C.
    Yoo, H.
    Han, C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S375 - S375
  • [9] STEREOTACTIC BODY RADIATION THERAPY FOR INTRAHEPATIC GRAFT RECURRENCE OF HEPATOCELLULAR CARCINOMA AFTER LIVER TRANSPLANTATION
    Piening, Alexander
    Shahi, Jeevin
    RADIOTHERAPY AND ONCOLOGY, 2024, 198 : S37 - S37
  • [10] Outcomes for Salvage Abdominal Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma after Liver Transplantation
    Stephens, C.
    Bloom, J.
    Lehrer, E. J.
    Sheu, R.
    Buckstein, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E181 - E181